Maze Therapeutics, Inc. (MAZE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 168 | 0 | 20 | 20 |
| Operating profit | $m | -143 | -146 | ||||||
| Net profit | $m | - | - | -115 | -100 | 52 | -131 | -134 | -110 |
| EPS reported | $ | -3.05 | -2.74 | ||||||
| Operating cashflow per share | $ | -2.60 | -1.81 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -2.62 | -1.81 | ||||||
| Free cash flow | $m | -113 | -107 | ||||||
| Net debt | $m | -342 | -372 | ||||||
| Book value equity | $m | 355 | 453 | ||||||
| Book value per share | $ | 8.26 | 7.68 | ||||||
| Number of shares | m | 42.98 | 59 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.02 | 3.93 | ||||||
| P/S LTM | x | 0.00 | 89.02 | ||||||
| P/FCF LTM | x | -15.79 | -16.67 | ||||||
| EV/EBITDA LTM | x | -12.54 | -12.39 | ||||||
| EV/Sales LTM | x | 0.00 | 66.16 | ||||||
| Earnings Yield LTM | % | -7.36% | -8.33% | ||||||
| FCF Yield | % | -6.33% | -6.00% | ||||||
| Quality | |||||||||
| ROE | % | -36.94% | -34.94% | ||||||
| ROIC | % | -37.67% | -28.35% | ||||||
| Operating margin | % | 0.00% | -7.28% | ||||||
| Gross margin | % | 0.00% | +95.28% | ||||||
| FCF/Sales | % | - | -534.20% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | -88.06% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.84 | -1.77 | ||||||
| Net Debt/EBITDA | x | 1.29 | 1.39 | ||||||
| EBIT/Net interest | x | 0.00 | -81.03 | ||||||
| Net debt/market cap | % | 0.00% | +1.10% | ||||||
| Net debt/Equity | x | -0.96 | -0.82 | ||||||
| Gross debt/equity | x | 0.07 | 0.13 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free